Intercept Pharmaceuticals, which is developing novel synthetic therapeutics for chronic liver diseases, raised $75 million by offering 5.0 million shares at $15, at high end of the range of $13 to $15. The company was able to raise an additional $11 million by offering an additional 700,000 shares. Intercept Pharmaceuticals plans to list on the NASDAQ under the symbol ICPT. BofA Merrill Lynch acted as the lead bookrunner on the deal.
